HCHF
13.5.2020 23:03:10 CEST | Business Wire | Press release
In response to the Higher Committee of Human Fraternity (HCHF) calls to pray for humanity today, 14th May, people of all races, colours, ethnicities, and nationalities stood together in an unprecedented event to pray and supplicate to God for an end to the COVID-19 pandemic, and to guide and inspire scientists find a vaccine.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005852/en/
From the very first moment the HCHF announced its great initiative, the call gained the blessing and support of the two most prominent religious leaders in the world; His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Pope of the Catholic Church, and received the support of a number of kings, presidents, leaders, and leading political, religious, and media figures from all the world.
Judge AbdelSalam, Secretary-General of the HCHF, held an online press conference on Monday, attended by Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis, and Irina Bokova, Former Director General of UNESCO during which he announced the details of the initiative in the presence of local and international media outlets.
Judge Mohamed AbdelSalam stated: “This support for the initiative is clear evidence that we can, especially when addressing common challenges, put aside our disagreements under the banner of our human fraternity. Believing that our common human values is the driving force for the HCHF’s members to announce the call to pray, fast and perform charitable work to rid mankind of this pandemic and its consequences.”
Judge AbdelSalam also announced the launch of the official website of the ‘Pray for Humanity’ initiative (pray.forhumanfraternity.org), which will provide live coverage of the day and will serve as a digital archive for this historic day and future events of the HCHF.
The HCHF was established to implement the humanitarian principles advocated by the Document on Human Fraternity and engage all religious and international organisations in this process to achieve peace, coexistence, global citizenship and human fraternity.
The HCHF consists of a group of influential figures of diverse religious and cultural backgrounds and experts in the fields of Inter-culture communication, interfaith dialogue and social coexistence:
- Cardinal Miguel Ángel Ayuso Guixot, President of the Pontifical Council for Interreligious Dialogue of the Holy See,
- Professor Mohamed Hussein Mahrasawi, President of Al-Azhar University,
- Judge Mohamed Mahmoud AbdelSalam, Former Advisor to the Grand Imam of Al-Azhar and the Secretary-General of the Committee,
- Rabbi M. Bruce Lustig, Senior Rabbi at Washington Hebrew Congregation,
- Irina Bokova, Former Director General of UNESCO,
- H.E. Mohamed Khalifa Al Mubarak, Chairman of the Department of Culture in Abu Dhabi,
- Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis,
- Dr. Sultan Al Remeithi, Secretary-General of the Muslim Council of Elders,
- Leymah Gbowee, a Liberian peace activist and Nobel Peace Laureate,
- Yasser Hareb, Emirati Writer and TV Presenter
- Father Professor Dr. Ioan Sauca, the Secretary-General of the World Council of Churches.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005852/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom